Dealbreaker on MSN4d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
Fierce Biotech5d
Beam gene therapy for protein deficiency passes early safety test, sets efficacy bar in space: analyst
The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...
BioPharma Dive5d
Beam base editing therapy gets ‘proof of concept’ in rare lung disease
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
Managed Healthcare Executive1d
First Clinical Proof of Genetic Mutation Correction for Rare Lung Disease
Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...
Mutated DNA Restored to Normal in Gene Therapy Advance
The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...
BioSpace4d
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.
pharmaphorum5d
Beam launches $500m financing on base-editing trial data
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...
Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition
The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...
The Week8d
What is Proton Beam Therapy, which is used to treat cancer?
Proton Beam Therapy is highly effective for treating tumours in sensitive areas, since by reducing exposure of healthy ...